Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISLB 2021 | ctDNA MRD as a biomarker for solid tumors

Aadel Chaudhuri, MD, PhD, Washington University School of Medicine, St. Louis, USA, discusses what research still needs to be done into using ctDNA as a biomarker for minimal residual disease (MRD) post-surgery for patients with solid tumors. Dr Chaudhuri also compares prognostic and predictive biomarkers. This interview took place at the International Society of Liquid Biopsy (ISLB) 2021 Virtual Meeting.